Stava-Murray supports HB4203 to broaden insurance for cancer screenings

Rep. Anne Stava-Murray (D-81st) supported HB4203, which proposes broadening insurance coverage for certain cancer screenings, during the 104th General Assembly on May 31, 2026. The Illinois House passed the measure by a unanimous 115-0 vote.

The official summary of the bill is: "INS CD-CANCER SCREENINGS."

Below is an overview, derived from the bill text, which interprets and clarifies its primary components.

The bill amends the Illinois Insurance Code to widen coverage for designated cancer screenings. It includes a high CA-125 level detected via blood test within its definition of those "at risk for ovarian cancer." HB4203 requires coverage—without cost-sharing—for annual cervical smear or Pap tests, yearly prostate cancer exams for specified individuals, and a variety of ovarian cancer surveillance procedures such as ultrasonography, MRI, x-ray, CT scans, and CA-125 blood testing. Certain limited scope insurance policies and high-deductible health plans for health savings accounts are not covered. If enacted, the law would go into effect Jan. 1, 2028.

The legislative record for HB4203 notes the action: 'Senate Floor Amendment No. 1 House Concurs.'

Stava-Murray received her BA from Dartmouth College in 2008.

First elected in 2019, Stava-Murray is a Democrat who succeeded David S. Olsen as the representative for Illinois' 81st House District.

Illinois legislation moves through a step-by-step process that starts with its introduction in either chamber, review in committee, consideration and votes on the chamber floors, and then final action from the governor. The General Assembly meets on a biennial basis; although each session sees thousands of bills introduced, only a portion advance through all hurdles to become law.